The possibility of cancer immune editing in gliomas. A critical review

被引：25

作者：

Arrieta, Victor A. ^{[1
]}

Cacho-Diaz, Bernardo ^{[2
]}

Zhao, Junfei ^{[3
]}

Rabadan, Raul ^{[3
]}

Chen, Li ^{[4
]}

Sonabend, Adam M. ^{[4
]}

机构：

[1] Univ Nacl Autonoma Mexico, PECEM, Fac Med, Mexico City, DF, Mexico

[2] Natl Canc Inst, Neurosci Unit, Mexico City, DF, Mexico

[3] Columbia Univ, Herbert Irving Comprehens Ctr, Dept Syst Biol, New York, NY USA

[4] Northwestern Univ, Dept Neurosurg, Feinberg Sch Med, 676 N St Clair St,Suite 2210, Chicago, IL 60611 USA

来源：

ONCOIMMUNOLOGY | 2018年 / 7卷 / 07期

关键词：

glioma; cancer immune editing; cancer genomics; equilibrium; escape; MHC CLASS-I; REGULATORY T-CELLS; MISMATCH REPAIR; GLIOBLASTOMA-MULTIFORME; INTERFERON-GAMMA; NUDE-MICE; MUTATIONAL LANDSCAPE; TUMOR SURVEILLANCE; DOWN-REGULATION; MSH6; MUTATIONS;

D O I：

10.1080/2162402X.2018.1445458

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The relationship between anti-tumoral immunity and cancer progression is complex. Recently, immune editing has emerged as a model to explain the interplay between the immune system and the selection of genetic alterations in cancer. In this model, the immune system selects cancer cells that grow as these are fit to escape immune surveillance during tumor development. Gliomas and glioblastoma, the most aggressive and most common of all primary malignant brain tumors are genetically heterogeneous, are relatively less antigenic, and are less responsive to immunotherapy than other cancers. In this review, we provide an overview of the relationship between glioma ' s immune suppressive features, anti-tumoral immunity and cancer genomics. In this context, we provide a critical discussion of evidence suggestive of immune editing in this disease and discuss possible alternative explanations for these findings.

引用

页数：9

共 87 条

[31] Regulation of cutaneous malignancy by γδ T cells [J].

Girardi, M ;

Oppenheim, DE ;

Steele, CR ;

Lewis, JM ;

Glusac, E ;

Filler, R ;

Hobby, P ;

Sutton, B ;

Tigelaar, RE ;

Hayday, AC .

SCIENCE, 2001, 294 (5542) :605-609

[32] The role of microglia and macrophages in glioma maintenance and progression [J].

Hambardzumyan, Dolores ;

Gutmann, David H. ;

Kettenmann, Helmut .

NATURE NEUROSCIENCE, 2016, 19 (01) :20-27

[33] Hallmarks of Cancer: The Next Generation [J].

Hanahan, Douglas ;

Weinberg, Robert A. .

CELL, 2011, 144 (05) :646-674

[34] Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape (Publication with Expression of Concern. See vol. 129, pg. 3464, 2019) [J].

Hegde, Meenakshi ;

Mukherjee, Malini ;

Grada, Zakaria ;

Pignata, Antonella ;

Landi, Daniel ;

Navai, Shoba A. ;

Wakefield, Amanda ;

Fousek, Kristen ;

Bielamowicz, Kevin ;

Chow, Kevin K. H. ;

Brawley, Vita S. ;

Byrd, Tiara T. ;

Krebs, Simone ;

Gottschalk, Stephen ;

Wels, Winfried S. ;

Baker, Matthew L. ;

Dotti, Gianpietro ;

Mamonkin, Maksim ;

Brenner, Malcolm K. ;

Orange, Jordan S. ;

Ahmed, Nabil .

JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (08) :3036-3052

[35] Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy [J].

Hodges, Tiffany R. ;

Ott, Martina ;

Xiu, Joanne ;

Gatalica, Zoran ;

Swensen, Jeff ;

Zhou, Shouhao ;

Huse, Jason T. ;

de Groot, John ;

Li, Shulin ;

Overwijk, Willem W. ;

Spetzler, David ;

Heimberger, Amy B. .

NEURO-ONCOLOGY, 2017, 19 (08) :1047-1057

[36] A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy [J].

Hunter, C ;

Smith, R ;

Cahill, DP ;

Stephens, P ;

Stevens, C ;

Teague, J ;

Greenman, C ;

Edkins, S ;

Bignell, G ;

Davies, H ;

O'Meara, S ;

Parker, A ;

Avis, T ;

Barthorpe, S ;

Brackenbury, L ;

Buck, G ;

Butler, A ;

Clements, J ;

Cole, J ;

Dicks, E ;

Forbes, S ;

Gorton, M ;

Gray, K ;

Halliday, K ;

Harrison, R ;

Hills, K ;

Hinton, J ;

Jenkinson, A ;

Jones, D ;

Kosmidou, V ;

Laman, R ;

Lugg, R ;

Menzies, A ;

Perry, J ;

Petty, R ;

Raine, K ;

Richardson, D ;

Shepherd, R ;

Small, A ;

Solomon, H ;

Tofts, C ;

Varian, J ;

West, S ;

Widaa, S ;

Yates, A ;

Easton, DF ;

Riggins, G ;

Roy, JE ;

Levine, KK ;

Mueller, W .

CANCER RESEARCH, 2006, 66 (08) :3987-3991

[37] Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors [J].

Jacobs, Joannes F. M. ;

Idema, Albert J. ;

Bol, Kalijn F. ;

Nierkens, Stefan ;

Grauer, Oliver M. ;

Wesseling, Pieter ;

Grotenhuis, J. Andre ;

Hoogerbrugge, Peter M. ;

de Vries, I. Jolanda M. ;

Adema, Gosse J. .

NEURO-ONCOLOGY, 2009, 11 (04) :394-402

[38] Extracranial glioblastoma in transplant recipients [J].

Jimsheleishvili, Sopiko ;

Alshareef, Ahmad T. ;

Papadimitriou, Kyriakos ;

Bregy, Amade ;

Shah, Ashish H. ;

Graham, Regina M. ;

Ferraro, Nicholas ;

Komotar, Ricardo J. .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (05) :801-807

[39] Liver graft-transmitted glioblastoma multiforme. A case report and experience with 13 multiorgan donors suffering from primary cerebral neoplasia [J].

Jonas, S ;

Bechstein, WO ;

Lemmens, HP ;

Neuhaus, R ;

Thalmann, U ;

Neuhaus, P .

TRANSPLANT INTERNATIONAL, 1996, 9 (04) :426-429

[40] Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice [J].

Kaplan, DH ;

Shankaran, V ;

Dighe, AS ;

Stockert, E ;

Aguet, M ;

Old, LJ ;

Schreiber, RD .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (13) :7556-7561

← 1 2 3 4 5 6 7 8 9 →